Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) announced on January 2, 2026 the filing of two U.S. provisional patent applications to expand its intellectual property into an oncology-focused dermatology platform.
The filings claim use of HT-001 to treat treatment-induced skin toxicities from radiation therapy and from emerging targeted cancer therapies (including second- and third-generation menin inhibitors), securing priority rights across multiple oncology modalities and formulations.
The company describes HT-001 as a receptor antagonist targeting neurogenic and inflammatory pathways and says the provisional filings support further preclinical work, formulation optimization, and potential future U.S. and international patent protection.
Positive
- Filed two U.S. provisional patents on Jan 2, 2026
- Secures priority IP for HT-001 across radiation and targeted-therapy skin toxicities
- Positions company in the growing oncology supportive-care/oncodermatology market
Negative
- Provisional applications are not granted patents and provide temporary priority only
- No clinical efficacy or outcome data for HT-001 in oncology dermatologic indications disclosed
- Further preclinical development and formulation work is required before regulatory or commercial milestones
Key Figures
Market Reality Check
Peers on Argus
Peers in Biotechnology showed mixed moves, with names like PASG up 12.92% and others such as LSTA and ELEV down modestly, suggesting HOTH’s setup around this IP news is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Pipeline update | Positive | +5.3% | Broad clinical and preclinical pipeline progress across four key programs. |
| Dec 01 | Conference presentation | Neutral | -5.8% | CEO presentation at NobleCon emerging growth equity conference. |
| Nov 20 | AI collaboration | Positive | -10.4% | Acceptance into NVIDIA Connect Program to support AI-driven R&D. |
| Oct 27 | Preclinical program launch | Positive | +1.1% | VA-backed GDNF study targeting obesity and fatty liver disease. |
| Oct 21 | Orphan designation | Positive | +3.6% | FDA Orphan Drug Designation and strong preclinical data for HT-KIT. |
News around pipeline and regulatory progress has often seen positive price alignment, though the NVIDIA AI collaboration drew a notable negative divergence.
Over the last few months, Hoth reported multiple R&D and strategic updates, including FDA Orphan Drug Designation and strong preclinical data for HT-KIT on Oct 21, 2025, a VA-backed GDNF obesity program launch on Oct 27, 2025, and acceptance into the NVIDIA Connect Program on Nov 20, 2025. A broad pipeline update on Dec 3, 2025 highlighted progress for HT-001, HT-KIT, HT-ALZ, and the GDNF program. Today’s dual oncology-dermatology patent filings for HT-001 extend this pattern of IP-focused, pipeline-building announcements.
Regulatory & Risk Context
An effective mixed shelf on Form S-3 filed Nov 14, 2025 allows Hoth to offer up to $50 million of various securities over time, plus resale of 1,279,587 shares by a selling shareholder. With 0 recorded usages so far and the shelf not yet effective, it still represents future capacity for potential equity or debt issuance that could impact existing shareholders depending on how it is utilized.
Market Pulse Summary
This announcement adds two U.S. provisional patents around HT-001, positioning it as a platform for treating radiation- and targeted-therapy–induced skin toxicities in oncology. It builds on prior updates highlighting a diversified, IP-heavy pipeline spanning HT-001, HT-KIT, HT-ALZ, and a GDNF metabolic program. Investors may focus on how this oncodermatology platform scales, future clinical-readout timing, the company’s cash of $7.85 million, and the existing $50 million shelf when assessing execution risk.
Key Terms
radiation-induced skin toxicity medical
dermatologic toxicities medical
menin inhibitors medical
receptor antagonist medical
pharmacologic profile medical
oncodermatology medical
AI-generated analysis. Not financial advice.
The first provisional patent application, titled covering the topical treatment of radiation-induced skin toxicity in oncology patients.
The second provisional patent application, titled addressing dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors.
Together, these dual filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents. As cancer treatments become more effective and patients remain on therapy longer, managing treatment-limiting skin toxicities has become a critical and growing unmet need in oncology care.
Radiotherapy-induced dermatitis and dermatologic adverse effects from targeted oncology therapies frequently result in pain, inflammation, severe pruritus, infection risk, reduced quality of life, and treatment interruption or discontinuation, which can negatively impact patient outcomes. Despite their prevalence, current treatment options remain largely supportive, with few mechanism-driven therapies designed to address the underlying biological drivers of these conditions.
Hoth's patent filings seek to protect the use of HT-001, a receptor antagonist with a well-established pharmacologic profile, to target neurogenic and inflammatory pathways implicated in therapy-induced skin injury. The Company believes this approach may represent a novel and potentially first-in-class strategy within the rapidly expanding oncology supportive-care and oncodermatology markets.
"These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care," said Robb Knie of Hoth Therapeutics. "As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value."
The Company believes these provisional patents support the development of a scalable oncology-adjacent platform with potential applications across radiation oncology, targeted cancer therapies, dermatology, and inflammatory skin disorders, while leveraging an established compound in novel therapeutic contexts, formulations, and routes of administration. The filings also provide flexibility to pursue additional preclinical development, formulation optimization, and future
Hoth Therapeutics continues to execute its strategy of building a diversified, IP-centric development portfolio focused on large, underserved markets, with an emphasis on therapies designed to improve patient outcomes and quality of life.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform-302651580.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What did Hoth Therapeutics (HOTH) announce on January 2, 2026?
What does a U.S. provisional patent filing mean for HOTH investors?
How does HT-001 aim to treat treatment-induced skin toxicity according to HOTH?
Which oncology therapies are covered by HOTH's new provisional filings for HOTH?
Do the filings mean HT-001 is ready for clinical use in oncology dermatology?
